Utilizing Capsoil’s patented nanometric powder technology can help the pharmaceutical industry overcome the limitations of poor solubility and bioavailability which are vital factors in drug effectiveness.

Drug absorption relies on solubility, as well as permeability. Poor dissolution in the fluids of the gastrointestinal tract can affect the bioavailability and efficacy of the drug. It is one of the most frequently encountered difficulties in the field of pharmaceuticals. Drugs with low bioavailability have limited therapeutic efficacy.

There are many significant hurdles for a pharma or biotech company to overcome during the drug development process. According to a Drug Development and Delivery study, only 1 in 5,000 discovery compounds will reach the market, and 1 in every 5 drug candidates will gain approval. The average time from drug discovery to product launch is estimated to be ~14 years. As a result, the overall costs of drug discovery and development to bring a new medicine to the market are estimated at over $1 billion for a new chemical entity (NCE).
Aqueous solubility of any therapeutically active substance is a key property, as it governs dissolution, absorption and thus the in vivo efficacy. If the problem is not overcome drug developers waste time and money on medications that will never make it to patients.

As a result, Capsoil’s nanometric powder can play an important role in overcoming these bioavailability challenges faced by pharma and the biotech industry. This especially important considering the cost new drug development as detailed above.

Lithophilic drugs molecules often require high doses to reach therapeutic plasma concentrations after oral administration, due to poor bioavailability. This high dosage can result in unnecessary side effects.

Consequently, the pharmaceutical industry needs innovative drug delivery technologies to overcome these bioavailability challenges.